fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ACR/ARHP 2013 Report – Triple DMARDs tops methotrexate in early rheumatoid arthritis

Written by | 21 Nov 2013

by Bruce Sylvester – Combined use of three DMARDs (disease-modifying antirheumatic drugs) for recent-onset rheumatoid arthritis (RA) is more effective than methotrexate monotherapy, researchers reported at the American… read more.

ACR/ARHP 2013 Report – Early and aggressive DMARD treatment improves outcomes in psoriatic arthritis

Written by | 19 Nov 2013

Treatment of psoriatic arthritis with early, aggressive pharmacologic intervention with disease-modifying antirheumatic drugs (DMARDs) while utilizing a a treat-to-target approach achieves  better outcomes than  standard care,  researchers reported … read more.

ACR/ARHP 2013 Report – Anti-TNF therapy lowers risk of acute coronary syndrome in rheumatoid arthritis

Written by | 19 Nov 2013

by Bruce Sylvester – Anti-TNF treatment reduces risk of acute coronary syndrome, like heart attacks and angina, in rheumatoid arthritis patients, researchers reported at the American College of… read more.

Smoking cessation drugs do not increase suicide/self-harm risk

Written by | 18 Nov 2013

by Bruce Sylvester – taken from the BMJ – British Medical Journal – Patients prescribed the smoking cessation drugs varenicline and buproprian are not at an increased risk… read more.

Drug combo effective for currently untreatable Hepatitis C

Written by | 18 Nov 2013

by Bruce Sylvester – taken from The Lancet – An investigative, single-pill combination drug shows efficacy for treating patients with the most difficult-to-treat types of hepatitis C, researchers… read more.

ECC 2013: Late Breaking Clinical Trials: ASPECCT

Written by | 15 Nov 2013

by Esther Drain reporting on the presentation by Dr Timothy Price – A randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated… read more.

1 in 4 patients with addictions have undiagnosed ADHD

Written by | 11 Nov 2013

People with Attention Deficit Hyperactivity Disorder (ADHD) are more vulnerable to developing an addictive disorder.

FDA Highlights: Meta-analysis suggests statins could prevent dementia and memory loss

Written by | 30 Oct 2013

by Bruce Sylvester – A new meta-analysis of clinical trials evaluating the use of statin medications to prevent heart attacks suggests that the drugs do not threaten short-term… read more.

ESOT 2013 Report – Pushing the limit in clinical science

Written by | 21 Oct 2013

by Peter Friend, Oxford, UK – The 16th ESOT Congress in Vienna 2013 was one of ESOT’s most comprehensive arrangements to date, with more than 3,500 attendees and… read more.

ESOT 2013 Report – Today’s patients, tomorrow’s outcomes: how can we manage risk factors to improve graft survival in renal transplantation?

Written by | 17 Oct 2013

by Maria Dalby – Kidney transplants could in principle last forever – the common assumption that kidney transplants inevitably deteriorate and fail is not supported by the latest… read more.

Inhaled corticosteroids increase risk of Pneumonia

Written by | 8 Oct 2013

by Bruce Sylvester – Investigators suggest caution in prescribing inhaled corticosteroids to high-risk patients such as pneumonia survivors, after their research shows a twofold risk for repeat infection.

Codeine could increase users’ sensitivity to pain

Written by | 27 Sep 2013

Using large and frequent doses of the pain-killer codeine may actually produce heightened sensitivity to pain, without the same level of relief offered by morphine, according to new… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.